Entera's EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation

Source · https://www.globenewswire.com/news-release/2026/05/28/3302886/0/en/Entera-s-EB613-First-in-Class-Oral-PTH-1-34-Anabolic-for-Osteoporosis-Single-Tablet-Data-Selected-for-Late-Breaking-Oral-Presentation-at-ENDO-2026-Annual-Meeting-Additional-Oral-Pe.html

Read source

Entera's EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation

Search tags

What matters in this story

Entera Bio's EB613 oral tablet has been selected as the final candidate for a planned Phase 3 study in postmenopausal women with osteoporosis. — Progression to Phase 3 is a critical clinical milestone that significantly increases the probability of commercialization and market entry.

+0.60

New clinical data for EB613 will be presented as a 'Late Breaking Oral Presentation' at the ENDO 2026 Annual Meeting. — Late-breaking oral presentations typically indicate high-impact or positive results, which can serve as a short-term catalyst for stock price.

+0.40

Entera is presenting pre-clinical data on EB612 for hypoparathyroidism and PK-PD study results for EB618 (a dual GLP-1/Glucagon receptor agonist) for obesity. — Development of oral alternatives for obesity (GLP-1) is a high-growth market sector, though these specific candidates are in earlier stages.

+0.30

Entera's EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation

What matters in this story

Valneva to Participate at U.S. and European Investor Conferences in June

Entera's EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation

What matters in this story

Valneva to Participate at U.S. and European Investor Conferences in June

Sentiment in this article

Relationships in this article

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

De nouvelles données "late-breaking" renforcent l’impact d’IQIRVO® sur l’ALP, la fatigue et le prurit dans la CBP.

New late-breaking data reinforces IQIRVO®’s impact on ALP, fatigue and pruritus in PBC

Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam

ALDEYRA DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 29 Deadline in Securities Class Action First Filed by the Firm - ALDX

ALDX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026

Entera's EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation

What matters in this story

Next reads from the same story arc

Valneva to Participate at U.S. and European Investor Conferences in June

Entera's EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation

What matters in this story

Next reads from the same story arc

Valneva to Participate at U.S. and European Investor Conferences in June

Sentiment in this article

Relationships in this article

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

De nouvelles données "late-breaking" renforcent l’impact d’IQIRVO® sur l’ALP, la fatigue et le prurit dans la CBP.

New late-breaking data reinforces IQIRVO®’s impact on ALP, fatigue and pruritus in PBC

Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam

ALDEYRA DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 29 Deadline in Securities Class Action First Filed by the Firm - ALDX

ALDX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026